AlphaYou
Overview
Smart money at a glance
Filings to Oct 5, 2026Net buying: insiders sold $0 and bought $109K on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- +$109K netNet buying
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 1 added, 1 cutEven
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Market overview
Fundamentals Oct 5- 52-wk high
- $156.00
- 52-wk low
- $60.10
- Prev close
- $79.80
- Mkt cap
- $2.77B
- P/E
- 20.7x
- Fwd P/E
- 37.3x
- Beta
- 1.88
- P/S
- 4.1x
- P/B
- 5.8x
- Profit margin
- +22.7%
- Op margin
- +12.5%
- ROE
- +36.3%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about TMDX filings
Are insiders buying or selling TransMedics Group Inc (TMDX) stock?
Net buying: insiders sold $0 and bought $109K of TMDX stock on the open market in the 90 days to Oct 5, 2026, according to SEC Form 4 filings. The largest was Weill, David (Director), who bought $109K. The latest filing was on Sep 14, 2026.
Which members of Congress have traded TMDX recently?
None. No member of Congress disclosed a TMDX trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this TMDX smart-money data?
This summary uses filings available on Oct 5, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position, insiders are trading both ways, and 1 fin-fluencer is discussing it.
What funds are doing
Buys/Adds (2)
- CI
Citadel
$31.0M
added
- MI
Millennium
$12.3M
added
Sells/Trims (1)
- TS
Two Sigma
$31.7M
trimmed
What insiders are doing
Buys (1)
- WD
Weill David
$109K
bought
Sells (1)
- GT
Gunderson Thomas J.
$722K
sold
How top traders are positioned
No tracked top-trader positions in TMDX right now.
Live Hyperliquid positioning - not every stock is covered
Activist stakes, short interest & more
Earnings
Earnings came in 12.0% below what analysts expected.
Last report
Aug 4, 2026
Period ending
Jun 30, 2026
Earnings per share
$0.50 expected
Revenue
No reported revenue on record
Previous reports
All values in USD| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 4, 2026 | $0.44 / $0.50Alpha Vantage | -12.00% miss | Unavailable | Unavailable |
| Mar 31, 2026 | May 5, 2026 | $0.30 / $0.61Alpha Vantage | -50.82% miss | Unavailable | Unavailable |
| Dec 31, 2025 | Feb 24, 2026 | $0.05 / $0.39Alpha Vantage | -86.94% miss | Unavailable | Unavailable |
| Sep 30, 2025 | Oct 29, 2025 | $0.66 / $0.36Alpha Vantage | +83.33% beat | Unavailable | Unavailable |
| Jun 30, 2025 | Jul 30, 2025 | $0.92 / $0.43Alpha Vantage | +113.95% beat | Unavailable | Unavailable |
| Mar 31, 2025 | May 8, 2025 | $0.70 / $0.24Alpha Vantage | +$0.46 beat | Unavailable | Unavailable |
| Dec 31, 2024 | Feb 27, 2025 | $0.19 / $0.22Alpha Vantage | -13.64% miss | Unavailable | Unavailable |
| Sep 30, 2024 | Oct 28, 2024 | $0.12 / $0.32Alpha Vantage | -62.50% miss | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Reports Nov 4, 2026, in 30 days
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $143.8M | $160.8M | $173.9M | $189.9M |
| Cost of what it sold | $59.2M | $67.3M | $72.8M | $76.8M |
| Gross profit | $84.6M | $93.4M | $101.2M | $113.2M |
| What it spent | ||||
| Research and development | $15.3M | $20.7M | $24.9M | $31.6M |
| Sales and admin | $44.9M | $50.2M | $55.7M | $53.5M |
| Other operating costs | $1.1M | $1.3M | $7.3M | $4.3M |
| Total operating expenses | $61.3M | $72.1M | $87.9M | $89.5M |
| What was left | ||||
| Operating profit | $23.3M | $21.3M | $13.3M | $23.7M |
| Interest on debt | $3.5M | $3.4M | $7.2M | $7.2M |
| Profit before tax | $23.0M | $21.6M | $8.5M | $19.4M |
| Tax | -$1.3M | -$83.8M | $1.2M | $4.7M |
| Net profit | $24.3M | $105.4M | $7.3M | $14.7M |
| EBITDA | $33.4M | $32.5M | $27.5M | $26.6M |
Technicals
Price structure
This stock is under pressure.
Trend
Under pressure
0 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage leans bullish
TransMedics Group Inc (TMDX) Shares Fall 5.8% -- What GF Score o
Leans bearishOct 2CapEx per share of TransMedics Group, Inc. – HAN:8T8
NeutralOct 1TransMedics Group (TMDX), Why Is It Back In The Spotlight?
Leans bullishOct 1TMDX5812024 Bond Profile: Coupon and Redemption
NeutralOct 1TransMedics CFO Fernando N. Araujo Files Initial SEC Ownership Disclosure Reporting No Shares
NeutralSep 29[Form 3] TransMedics Group, Inc. Initial Statement of Beneficial Ownership
NeutralSep 29Net margin % of TransMedics Group, Inc. – HAN:8T8
NeutralSep 29TransMedics Director David Weill Purchases $109,000 of Stock -- Should Investors Buy Too?
BullishSep 29
Macro
11 macro signals shaping TMDX right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results